Abstract
Ceftazidime (CAZ), a new cephalosporin antibiotic, was fundamentally and clinically studied. The follow-ing results were obtained.
1. Serum and internal genital tissue levels of CAZ were measured following intravenous drip infusion of 1g for 30 minutes.
Serum levels of more than 10 μg/ml and tissue levels of more than about 7 μg/ml were maintained after 2 hours to 2 hours and 30 minutes, respectively. Favourable transfer of CAZ into the pelvic dead space exudate was observed. The exudate level attained its peak of 31.54 μg/ml on average at 2 hours and was 16.8 μg/ml on average even at 8 hours after intravenous drip infusion.
2. A total of 6 cases comprising 1 of adnexitis, 2 of pyometra, 1 of endometritis and 2 of parametritis was treated with CAZ at a dose of 0.5-2.0g twice daily by intravenous injection or intravenous drip infusion.
The clinical response was excellent in 1 case, good in 4 cases and poor in 1 case. Abnormal laboratory findings and side effects due to the drug were not noted.
